

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Fletcher, Tom E; Bower, Hilary; (2019) Unrecognised Ebola virus infection in contact persons: what can we learn from it? *Lancet Infectious Diseases*. ISSN 1473-3099 DOI: [https://doi.org/10.1016/S1473-3099\(18\)30689-3](https://doi.org/10.1016/S1473-3099(18)30689-3)

Downloaded from: <http://researchonline.lshtm.ac.uk/4649947/>

DOI: [https://doi.org/10.1016/S1473-3099\(18\)30689-3](https://doi.org/10.1016/S1473-3099(18)30689-3)

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

1 Title: Unrecognised Ebola virus infection in contacts: what can we learn from it?

2 Tom E Fletcher and Hilary Bower

- 3 1. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA,
4 tom.fletcher@lstmed.ac.uk
- 5 2. UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine,
6 Keppel Street, London WC1E 7HT

7 Word count 701

8 The epidemic of Ebola virus disease (EVD) in West Africa in 2014-2016 was the largest and most
9 complicated the world has ever seen. The four pillars of Ebola response include: case management;
10 case finding and contact tracing; safe and dignified burial; and social mobilisation and community
11 engagement. These are being implemented in the current outbreak in the Democratic Republic of
12 Congo (DRC), that is further complicated by its location in a conflict zone¹. Increased understanding
13 of disease pathogenesis and the evaluation of novel therapeutics and vaccine candidates has
14 informed current control measures, whilst access to survivors and their contacts in West Africa also
15 provides a unique opportunity to research Filovirus transmission.

16 In their article published in *The Lancet Infectious Diseases*, Diallo and colleagues (ref) report data
17 from a large cross-sectional study of contacts of an established survivor cohort in Guinea. They
18 aimed to estimate the frequency of unrecognised Ebola virus infection (EVI) in contacts, after
19 excluding those that were vaccinated, and to identify risk factors for infection. Utilising a novel and
20 previously validated Luminex assay ² on dried blood spots, and detailed retrospective exposure
21 histories they identified 57 EVIs among 1390 contacts (4.1%).

22 They demonstrated increased seropositivity in contacts who reported any symptom associated with
23 EVD (8.33%; 95% CI: 5.01% to 12.80%, described as paucisymptomatic contacts) compared to EVI in
24 asymptomatic contacts (3.32%; 95% CI: 2.37% to 4.51%, $p=0.0002$). Participation in burial rituals and
25 contact with blood or vomit were independent significant risk factors for EVI in asymptomatic
26 contacts in multivariate analysis, whilst older age and participation in burial practices were risk
27 factors in paucisymptomatic cases. Their findings concur with a recent meta-analysis of
28 seroprevalence surveys ³ and the results of a study in Sierra Leone of 486 household members of
29 EVD survivors, which identified EVI in 12% (95% CI: 6.1–20.4) of those with symptoms compared to
30 2.6% (95% CI: 1.2–4.8) of asymptomatic household members⁴. The same study also demonstrated
31 that burial contact and older age were risk factors for EVI⁵.

32 The conclusions drawn by Diallo et al reaffirm the challenges/failures in case finding and contact
33 tracing highlighted by others in Guinea⁶. This is evidenced by the 73% of paucisymptomatic contacts
34 who, in reporting a history of fever, met the WHO definitions for suspect cases that required
35 isolation and further evaluation^{7,8}. Furthermore, they highlight that 30/216 paucisymptomatic
36 contacts met the EVD suspect case definition without contact but were not diagnosed acutely, of
37 whom 20% were seropositive. These results are timely as in the DRC, as of 23 October, 5723
38 contacts remain under surveillance, with follow-up rates ranging from 85-97% ⁹. The data from
39 Diallo et al highlights the varying spectrum of EVD severity, consistent with early clinical reports in
40 West Africa¹⁰, and again challenges our perceptions of the roles and balance of viral infective dose
41 and host immune response in clinical phenotypes. Studies like this may be unique, and impossible to
42 replicate, because of the scale of the West African outbreak and the now-established practice of ring
43 vaccination.

44 Care must also be taken in the interpretation and extrapolation of these results. As the authors
45 acknowledge, there is risk of recall bias: it is challenging to remember clinical symptoms, exposure
46 and exact timing over two years after the event. The key 'question' is whether these unidentified EVI
47 contacts had any role in transmission chains. This issue was recently highlighted by Dokubo et al ¹¹,
48 who reported a familial cluster occurring in Liberia one year after an undiagnosed EVI in a female
49 contact, due to viral persistence. This potential transmission risk must be balanced against the risk
50 of further stigmatisation of both survivors and household contacts.

51 This study reinforces the importance of robust and detailed contact tracing as a control measure and
52 highlights the high risk posed by burial practices and direct contact with infected fluids. What is also
53 notable is how few contacts (>90%) who reported high-risk exposures were infected. Greater
54 understanding is needed about the mechanisms of Ebola virus transmission in order to improve the
55 targeting of interventions as part of a coordinated response. Epidemics of Ebola virus disease remain
56 a major risk to healthcare workers and populations in endemic regions, as well as a global threat to
57 health security.

58 TF and HB declare no competing interests

- 59 1 The Lancet. DR Congo: managing Ebola virus in war. *Lancet* 2018; **392**: 1280.
- 60 2 Ayouba A, Touré A, Butel C, *et al*. Development of a sensitive and specific serological assay
61 based on Luminex technology for detection of antibodies to Zaire Ebola Virus. *J Clin Microbiol*.
62 2017; **55**: 165–76.
- 63 3 Bower H, Glynn JR. A systematic review and meta-analysis of seroprevalence surveys of
64 ebolavirus infection. *Sci Data* 2017; **4**: 160133.
- 65 4 Glynn JR, Bower H, Johnson S, *et al*. Asymptomatic infection and unrecognised Ebola virus
66 disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new
67 non-invasive assay for antibodies to Ebola virus. *Lancet Infect Dis* 2017; **17**: 645–53.
- 68 5 Bower H, Johnson S, Bangura MS, *et al*. Exposure-specific and age-specific attack rates for
69 Ebola virus disease in Ebola-affected households, Sierra Leone. *Emerg Infect Dis*. 2016; **22**:
70 1403–11.
- 71 6 Dixon MG, Taylor MM, Dee J, *et al*. Contact tracing activities during the Ebola virus disease
72 epidemic in Kindia and Faranah, Guinea, 2014. *Emerg Infect Dis* 2015; **21**: 2022–8.
- 73 7 World Health Organisation. Regional office for Africa. Contact tracing during an outbreak of
74 Ebola virus disease. [http://www.who.int/csr/resources/publications/ebola/contact-tracing-](http://www.who.int/csr/resources/publications/ebola/contact-tracing-during-outbreak-of-ebola.pdf)
75 [during-outbreak-of-ebola.pdf](http://www.who.int/csr/resources/publications/ebola/contact-tracing-during-outbreak-of-ebola.pdf). [last accessed 29/10/18]
- 76 8 World Health Organization. Clinical management of patients with viral haemorrhagic fever: a
77 pocket guide for the front-line health worker. 2014.
78 <http://www.who.int/csr/resources/publications/clinical-management-patients/en/> [last
79 accessed 29/10/18]
- 80 9 World Health Organization. Ebola virus disease – Democratic Republic of the Congo. *Dis*
81 *outbreak news* 2018. <http://www.who.int/csr/don/25-october-2018-ebola-drc/en/>. [last
82 accessed 29/10/18]
- 83 10 Fowler RA, Fletcher T, Fischer WA, *et al*. Caring for critically ill patients with Ebola virus
84 disease: Perspectives from West Africa. *Am J Respir Crit Care Med* 2014; **190**: 733-737.
- 85 11 Dokubo EK, Wendland A, Mate SE, *et al*. Persistence of Ebola virus after the end of
86 widespread transmission in Liberia: an outbreak report. *Lancet Infect Dis* 2018; **18**: 1015–24.

